Nice !Nice to see they press released the full move into Columbia.
I remember looking through the agreement with Novartis and there were many redactions. Makes you wonder what is so "business sensitive" and "financially sensitive" with these labels added at the redactions.
"On May 26, 2021, Knight completed the acquisition of the exclusive rights to manufacture, market and sell Exelon® in Canada and Latin America as well as the exclusive license to use the intellectual property and the Exelon trademark, from Novartis within those territories."
What do you think their purpose is w.r.t. "use" the intellectual property? Would that just be in the manufacturing process or is there more to it?